Morgan Stanley’s BeOne Medicines Ltd ONC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $142M | Buy |
497,437
+32,965
| +7% | +$9.71M | 0.01% | 1282 |
|
|
2026
Q1 | $138M | Buy |
464,472
+26,811
| +6% | +$8.68M | 0.01% | 1183 |
|
|
2025
Q4 | $133M | Buy |
437,661
+84,367
| +24% | +$27.6M | 0.01% | 1206 |
|
|
2025
Q3 | $120M | Buy |
353,294
+84,820
| +32% | +$25.8M | 0.01% | 1258 |
|
|
2025
Q2 | $65M | Sell |
268,474
-143,455
| -35% | -$35.2M | ﹤0.01% | 1672 |
|
|
2025
Q1 | $112M | Sell |
411,929
-326,211
| -44% | -$76.3M | 0.01% | 1172 |
|
|
2024
Q4 | $136M | Buy |
738,140
+565,108
| +327% | +$115M | 0.01% | 1043 |
|
|
2024
Q3 | $38.8M | Buy |
173,032
+87,199
| +102% | +$15.7M | ﹤0.01% | 2099 |
|
|
2024
Q2 | $12.2M | Sell |
85,833
-36,945
| -30% | -$5.69M | ﹤0.01% | 3155 |
|
|
2024
Q1 | $19.2M | Sell |
122,778
-38,256
| -24% | -$6.16M | ﹤0.01% | 2745 |
|
|
2023
Q4 | $29M | Buy |
161,034
+15,452
| +11% | +$2.8M | ﹤0.01% | 2284 |
|
|
2023
Q3 | $26.2M | Sell |
145,582
-35,761
| -20% | -$7.08M | ﹤0.01% | 2177 |
|
|
2023
Q2 | $32.3M | Buy |
181,343
+25,437
| +16% | +$5.86M | ﹤0.01% | 1986 |
|
|
2023
Q1 | $33.6M | Sell |
155,906
-25,771
| -14% | -$6.18M | ﹤0.01% | 1908 |
|
|
2022
Q4 | $40M | Sell |
181,677
-9,413
| -5% | -$1.73M | ﹤0.01% | 1691 |
|
|
2022
Q3 | $25.8M | Buy |
191,090
+47,833
| +33% | +$8.21M | ﹤0.01% | 1923 |
|
|
2022
Q2 | $23.2M | Buy |
143,257
+25,328
| +21% | +$3.96M | ﹤0.01% | 2124 |
|
|
2022
Q1 | $22.2M | Sell |
117,929
-36,815
| -24% | -$7.83M | ﹤0.01% | 2002 |
|
|
2021
Q4 | $41.9M | Buy |
154,744
+26,820
| +21% | +$9.06M | 0.01% | 1476 |
|
|
2021
Q3 | $46.4M | Buy |
127,924
+13,422
| +12% | +$4.39M | 0.01% | 1341 |
|
|
2021
Q2 | $39.3M | Buy |
114,502
+77,060
| +206% | +$25.5M | 0.01% | 1502 |
|
|
2021
Q1 | $13M | Sell |
37,442
-21,603
| -37% | -$7.15M | ﹤0.01% | 2375 |
|
|
2020
Q4 | $15.3M | Sell |
59,045
-5,686
| -9% | -$1.57M | ﹤0.01% | 2072 |
|
|
2020
Q3 | $18.5M | Buy |
64,731
+6,259
| +11% | +$1.47M | ﹤0.01% | 1540 |
|
|
2020
Q2 | $11M | Buy |
58,472
+39,247
| +204% | +$6.39M | ﹤0.01% | 1883 |
|
|
2020
Q1 | $2.37M | Buy |
19,225
+8,980
| +88% | +$1.4M | ﹤0.01% | 3220 |
|
|
2019
Q4 | $1.7M | Buy |
10,245
+2,002
| +24% | +$333K | ﹤0.01% | 4163 |
|
|
2019
Q3 | $1.01M | Sell |
8,243
-76,664
| -90% | -$10.2M | ﹤0.01% | 4294 |
|
|
2019
Q2 | $10.5M | Sell |
84,907
-110,559
| -57% | -$14M | ﹤0.01% | 2105 |
|
|
2019
Q1 | $25.8M | Sell |
195,466
-122,253
| -38% | -$16.5M | 0.01% | 1266 |
|
|
2018
Q4 | $44.6M | Sell |
317,719
-34,105
| -10% | -$4.52M | 0.01% | 874 |
|
|
2018
Q3 | $60.6M | Sell |
351,824
-148,652
| -30% | -$25M | 0.02% | 840 |
|
|
2018
Q2 | $76.9M | Buy |
500,476
+142,078
| +40% | +$25.3M | 0.02% | 701 |
|
|
2018
Q1 | $60.2M | Sell |
358,398
-28,502
| -7% | -$3.86M | 0.02% | 814 |
|
|
2017
Q4 | $37.8M | Buy |
386,900
+187,303
| +94% | +$17.1M | 0.01% | 1139 |
|
|
2017
Q3 | $20.7M | Buy |
199,597
+196,597
| +6,553% | +$14.6M | 0.01% | 1553 |
|
|
2017
Q2 | $135K | Sell |
3,000
-2,795
| -48% | -$110K | ﹤0.01% | 5512 |
|
|
2017
Q1 | $212K | Buy |
5,795
+2,146
| +59% | +$78.2K | ﹤0.01% | 5302 |
|
|
2016
Q4 | $111K | Buy |
3,649
+1,298
| +55% | +$40.8K | ﹤0.01% | 5538 |
|
|
2016
Q3 | $73K | Sell |
2,351
-167
| -7% | -$4.85K | ﹤0.01% | 5438 |
|
|
2016
Q2 | $75K | Sell |
2,518
-5,939
| -70% | -$174K | ﹤0.01% | 5377 |
|
|
2016
Q1 | $248K | Buy |
+8,457
| New | +$240K | ﹤0.01% | 4848 |
|
Other funds holding ONC
BBA
Morgan Stanley's ONC Position: Q2 2026 in Review
Morgan Stanley increased its BeOne Medicines Ltd (ONC) stake by 7.1% in Q2 2026, buying an estimated $9.71M and bringing the position to 497,437 shares worth $142M. The position accounts for 0.01% of the portfolio, ranked #1282.
Morgan Stanley first reported a position in ONC in Q1 2016 and has held it in 42 quarters since. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.
- Morgan Stanley held 497,437 shares of BeOne Medicines Ltd worth $142M as of Q2 2026.
- Morgan Stanley bought 32,965 BeOne Medicines Ltd shares in Q2 2026, an estimated $9.71M.
- BeOne Medicines Ltd made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1282 holding.
- Morgan Stanley first reported a position in BeOne Medicines Ltd in Q1 2016 and has held it in 42 quarters since.
- 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.